KALV
KalVista Pharmaceuticals, Inc.NASDAQHealthcareAs of 2026-04-06
Valuation
View DetailsP/E (TTM)
—
PEG
—
P/B
-370.96
P/S
13.58
EV/EBITDA
-6.56
DCF Value
$2.06
FCF Yield
-8.0%
Div Yield
0.0%
Margins & Returns
Gross Margin
68.7%
Operating Margin
-231.1%
Net Margin
-222.8%
ROE
-444.4%
ROA
-49.8%
ROIC
-57.9%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2026 | $59.9M | $-5.4M | $-0.11 |
| Q2 2026 | $13.7M | $-49.5M | $-0.92 |
| Q1 2026 | $1.4M | $-60.1M | $-1.12 |
| Q4 2025 | $0.00 | $-52.2M | $-1.05 |
Analyst Ratings
View AllTrading Activity
Insider Trades
View AllCompany Info
Sector
Healthcare
Industry
—
Country
US
Exchange
NASDAQ
Beta
-0.40
KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors for diseases with unmet needs. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors. Its products include KVD001, a plasma kallikrein inhibitor that completed a Phase II clinical trial for the treatment of DME; sebetralstat, which is initiation of the Phase 3 KONFIDENT trial as a potential oral, on-demand therapy for HAE attacks; KVD824, an oral product candidate for the treatment of HAE; and Factor XIIa, an oral inhibitor program which is in preclinical stage targets an enzyme in HAE. The company is headquartered in Cambridge, Massachusetts.